Identification of commonly regulated genes in HPV18- and HPV16-infected cervical cancer cells treated with the curcumin analogue 1,5-bis(2-hydroxyphenyl)-1,4-pentadiene-3-one

Felicia Paulraj¹, Faridah Abas²,³, Nordin H. Lajis², Iekhsan Othman¹, Sharifah Syed Hassan¹, Rakesh Naidu¹∗

¹Jeffrey Cheah School of Medicine & Health Sciences, Monash University Malaysia, Jalan Lagoon Selatan, Bandar Sunway 47500, Selangor, Malaysia
²Laboratory of Natural Products, Faculty of Science, Universiti Putra Malaysia, UPM Serdang 43400, Selangor, Malaysia
³Department of Food Science, Faculty of Food Science and Technology, Universiti Putra Malaysia, UPM Serdang 43400, Selangor, Malaysia

∗Corresponding author: Dr. Rakesh Naidu, Jeffrey Cheah School of Medicine and Health Sciences, Monash University Malaysia, Jalan Lagoon Selatan, Bandar Sunway, Selangor Darul Ehsan, Malaysia.
Telephone: + 603 55146345
E-mail: kdrakeshna@hotmail.com
Foundation project: This study is financially supported by the Fundamental Research Grant Scheme (No. FRGS/1/2013/SKK01/MUSM/02/1) under the Ministry of Higher Education, Malaysia.

ARTICLE INFO
Article history:
Received 16 October 2017
Revision 15 November 2017
Accepted 1 December 2017
Available online 1 January 2018

Keywords:
Diarylpentanoid
Cervical cancer
Gene expression profiling
Microarray
Curcumin analogue

ABSTRACT
Objective: To identify commonly regulated genes in HPV-infected HeLa and CaSki cervical cancer cells treated with curcumin analogue 1,5-bis(2-hydroxyphenyl)-1,4-pentadiene-3-one (MS17) and to explore potential mechanisms that underlie its cytotoxic, anti-proliferative and apoptotic activity.

Methods: HeLa and CaSki cells were treated with 2 × EC50 and 3 × EC50 doses of MS17 for 24 h and the RNA extracts were subjected to one-colour microarray-based gene expression profiling. Pair-wise significant genes (false discovery rate-corrected, P<0.05) were analysed for fold change (FC) compared to control samples. Differentially expressed genes with FC ≥ 2.0 (up-regulated; FC ≥ 2.0 and down-regulated; FC ≤ -2.0) compared to the control samples were filtered through and analysed to create a global gene expression profile. Mutually regulated genes were ranked by FC and categorised by gene ontology.

Results: Our data indicated dose-dependent regulation by MS17 and identified top 20 mutually up-and down-regulated genes each in HeLa and CaSki cells. Amongst these 17 were commonly regulated in both cell lines. These include the up-regulation of CCL26, DEFB103B, IL1RL1, LY96, GCNT3, MMP10, MMP3, GADD45G and HSPA6, and the down-regulation of TENM2, NEBL, KIFC1, CTDSP1, IGFBP5, LTBP1, NREP and MXD3. These genes were associated with key biological functions that were proposed to mediate the anticancer activity of MS17 in cervical cancer cells such as immune response, metabolic processes, protein synthesis, programmed cell death, unfolded protein response, cell adhesion, cytoskeletal organisation, phosphatase activity, signal transduction and transcription regulatory activity.

Conclusions: Identification of seventeen common genes modulated by MS17 could be used as potential therapeutic targets in both cervical cancer cell lines and the findings of this study could be used to present an insight into the potential antitumor activity of MS17 in cervical cancer.

1. Introduction

Cervical cancer is the fourth most common cancer affecting women worldwide¹ and ranks as the second most frequent cancer affecting Malaysian women. Curcumin is a widely studied phytochemical.

This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-Share Alike 3.0 License, which allows others to remix, tweak and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

For reprints contact: reprints@medknow.com
©2018 Asian Pacific Journal of Tropical Biomedicine Produced by Wolters Kluwer-Medknow

How to cite this article: Paulraj F, Abas F, Lajis NH, Othman I, Hassan SS, Naidu R. Identification of commonly regulated genes in HPV18- and HPV16-infected cervical cancer cells treated with the curcumin analogue 1,5-bis(2-hydroxyphenyl)-1,4-pentadiene-3-one. Asian Pac J Trop Biomed 2018; 8(1): 44-51.
The treatment of cervical cancer cells with curcumin activates caspase-3-mediated apoptosis, restores p53 and pRb expression and inhibits AP-1 and NF-xB activity[2-4]. Notably, curcumin demonstrates potential antiviral activity due to its ability to inhibit the expression of E6 and E7 viral oncogenes[5,6] which significantly increases the cytotoxic and apoptotic effects of curcumin treatment on cervical cancer cells[7]. Synthetic 1,5-diaryl-3-oxo-1,4-pentadiene curcumin analogues known as diarylpentanoids reported greater growth suppressive effects in cancer cells over curcumin or other 7-carbon curcumin analogues[8]. Similarly with curcumin, these diarylpentanoids mediated programmed cell death, mitotic arrest and anti-proliferative effects in numerous cancer cell lines via a wide variety of molecular targets including p53, NF-xB, STAT3, c-Myc and PTEN[9-11]. EF24 is the most studied DAP to date due to its ability to collectively target molecules that induce, among others, anti-proliferative, apoptotic, anti-angiogenesis and anti-oxidative effects in cancer cells[12-14]. The treatment of HeLa cervical cancer cells by EF24 demonstrated the inhibition of cell viability via the suppression of NF-xB signaling[14], and studies by two other groups reported the potential anti-proliferative and apoptotic effects of treatment on cervical cancer cells[15,16]. Recently, a PGA-based curcumin nanoparticle formulation has been shown to effectively inhibit growth, induce apoptosis and cause cell cycle arrest in CaSki and SiHa cervical cancer cell lines[17]. Beyond these studies however, the anticancer effect of diarylpentanoids on cervical cancer cell lines have not been extensively studied.

We have previously established[18] that treatment of 1,5-bis(2-hydroxyphenyl)-1,4-pentadiene-3-one, known as MS17, on CaSki and HeLa cervical cancer cells demonstrated significant cytotoxic and anti-proliferative activity compared to curcumin. MS17 also demonstrated significant down-regulation of HPV18- and HPV16-associated E6 and E7 oncogene expression following treatment. Furthermore, MS17-exposed cells exhibited significant morphological changes consistent with apoptosis at their respective 2×EC50 (HeLa: 6 µM, CaSki: 4 µM) and 3×EC50 (HeLa: 9 µM, CaSki: 6 µM) dosages at 24 h of treatment. This suggested that an increase in treatment dose by 1.5-fold was able to effect apoptotic changes within the cells. To the best of our knowledge, this is the first report of its kind on HPV-positive cervical cancer cells. To investigate the mechanisms of action of the MS17 curcumin analogue on cervical cancer cells at a molecular level, microarray-based gene expression profiling of MS17-treated HPV-18 infected HeLa and HPV-16 infected CaSki cells was performed. Dose-dependent changes in gene regulation that occurred in response to treatment were analysed and the regulation of 17 genes that were mutual to both cervical cancer cell lines were identified as potential common targets of MS17. The molecular changes in the regulation of these genes that potentially justifies the cytotoxic, anti-proliferative and apoptotic activity of MS17 on cervical cancer cells have been presented here and discussed.

2. Materials and methods

2.1. Cell culture and preparation of MS17

HPV-infected HeLa and CaSki cervical cancer cell lines were obtained from American Type Culture Collection (ATCC, Rockville, MD, USA) and maintained using MEM and RPMI 1640 (Gibco) culture media respectively and supplemented with 10% Fetal Bovine Serum (FBS, Gibco) and penicillin (100 U/mL)/streptomycin (100 µg/mL) (Gibco). Cells were cultured at 37 °C in a humidified atmosphere with 5% CO2. The curcumin analogue 1,5-bis(2-hydroxyphenyl)-1,4-pentadiene-3-one (MS17) was prepared as previously described[18].

2.2. Treatment of cervical cancer cells and total RNA extraction

Cancer cells were plated at 4×104 cells per mL in 1 mL culture medium per well as described earlier[18], exposed to MS17 at their respective doses for 24 h and prepared for RNA extraction. Experiments were performed in triplicate and included a set of untreated control cells (media with DMSO alone). Total RNA was extracted using the Qiagen RNeasy® Mini Kit (Qiagen, Valencia, CA., USA) according to the manufacturer’s instructions. RNA samples with an A260/A280 and A260/A230 ratio of ≥1.9 and with a RNA integrity number score of approximately ≥8 were selected for gene expression profiling.

2.3. Microarray analysis

Agilent oligonucleotide microarrays were used for one-colour gene expression analysis and samples were prepared according to the protocols provided by One-Color Low Input Quick Amp labeling kit (Agilent, Valencia, CA, USA). Information from features on the array was extracted using Agilent’s Feature Extraction Software 11.5.1 (Agilent Technologies, 2004, USA) and analysed (GeneSpring GX version 13.0 software, Agilent, USA). Normalisation was performed using Agilent Single Color 28004 Technology. Raw signals were log transformed, normalized and baseline transformed to the median of all samples. Values were normalised by shifting to the 75th percentile. Probes were subjected to additional steps of filtering on detected flags and expression value. Filtering on expression removes probes with low raw signal intensities (<20) and entities where at least 100 percent of samples in any 1 out of 4 conditions have values exceeding 20 qualified to proceed to the next filtering criteria.

2.4. Statistical analysis

Statistical analysis was performed using analysis of variance with Benjamini-Hochberg false discovery rate multiple testing correction, followed by a post hoc testing using Tukey’s Honestly Significant Difference to identify pair-wise significant genes. Genes that passed the significance threshold with a false discovery rate-corrected adjusted P-value of P<0.05 was analysed for its fold change (FC) compared to control samples. FC measures the relative change in expression between treatment (MS17-treated samples) and control (DMSO-treated) conditions for a particular gene. Differentially expressed genes (DEGs) with FC ≥2.0 (up-regulated; FC ≥2.0 and down-regulated; FC ≤-2.0) compared to the control samples were filtered through and analysed to create a global gene expression profile. Hierarchical cluster analysis was performed on this DEG list using software-recommended parameters.
2.5. Data analysis

For an analysis on the dose-dependent regulation of genes by MS17, downstream analysis focused on selected mutually regulated DEGs in MS17-treated HeLa (6 µM and 9 µM) and CaSki (4 µM and 6 µM) cells. The top twenty DEGs that were mutually up-regulated and down-regulated each in both cell lines were selected to obtain a list of top ranked genes. Ontological analysis of mutually regulated genes was performed using the Database for Annotation, Visualisation and Integrated Discovery (DAVID)[10] which is freely accessed at http://david.abcc.ncifcrf.gov. Gene symbols of mutually expressed genes from each cell line were submitted to DAVID. Annotations were limited to ‘Homo sapiens’ and gene ontological (GO) analysis was performed using the functional annotation tool and further analysed using the GO functional categories which provide a description of associated biological processes and molecular functions for the selected genes. Genes were grouped into functional categories based on the exported GO terms from DAVID.

2.6. Validation of microarray results by quantitative real-time PCR

To assess the robustness of the microarray analysis, quantitative real-time PCR analysis was performed to validate a selected panel of DEGs (CCL26, MMP10, MMP3, CTDSP1, IGFBP5 and MXD3) and normalised against the endogenous gene, human glyceraldehyde 3-phosphate dehydrogenase (GAPDH). Complementary DNA was generated from the RNA isolated from MS17-treated HeLa and CaSki cells that were used for microarray profiling following the previously described protocol[18]. Transcript levels of the selected DEGs and GAPDH were measured by TaqMan® Gene Expression Assays specific to each gene. The primers and TaqMan probe sequences used for the selected genes corresponded to assay IDs (CCL26, Hs001711146_m1; MMP10, Hs00233987_m1; MMP3, Hs00996308_m1; CTDSP1, Hs01105503_m1; IGFBP5, Hs01052295_m1; MXD3, Hs00361007_m1; GAPDH, Hs99999905_m1) acquired from the TaqMan Gene Expression Assay database (Applied Biosystems, USA). Samples were prepared according to manufacturer’s instructions and loaded into the StepOnePlus™ real-time PCR system (Applied Biosystems), cycled using the Fast run method and relative mRNA expression levels of the target genes were calculated using the comparative Ct method. Each reaction was run in duplicates and fold change expression of mRNA results from quantitative real-time PCR was converted to log2 fold change and represented in bar graphs alongside log2 fold change data from microarray analyses. The bar graph representing the results was constructed using GraphPad Prism version 6.00 for Windows, GraphPad Software (San Diego, CA, USA).

3. Results

Based on dosages that were previously established to induce apoptosis, HeLa was exposed to 6 µM and 9 µM, while CaSki was exposed to 4 µM and 6 µM of MS17 for 24 h. Only significant entities that demonstrated a P-value of P<0.05 and were differentially expressed compared to the control by a fold change greater than or equal to 2.0 (FC ≥ 2.0) were considered for analysis. Amongst these genes, 1 167 and 1 836 genes in HeLa were differentially expressed by 6 µM and 9 µM treatment respectively while in CaSki, 1 069 and 1 091 genes were differentially expressed by 4 µM and 6 µM treatment. DEGs were subjected to a hierarchical cluster analysis from which a dose-dependent effect of MS17 treatment on both HeLa and CaSki gene regulation was suggested as 826 genes in HeLa and 491 genes in CaSki composed DEGs that were mutually expressed by both treatment doses. Of these DEGs, we have identified top 20 mutually up- and down-regulated genes each in HeLa and CaSki cells.

Ontological classification was performed on the top 20 ranking genes that were differentially regulated by MS17 treatment and mutually expressed by both treatment doses in HeLa (Table 1) and CaSki (Table 2) cells. These genes were subsequently grouped according to their respective biological functions. Amongst the top 20 genes, 17 genes were commonly regulated by MS17 in both cell lines (denoted as asterisks in Table 1 and Table 2). These included the up-regulation of CCL26, DEFB103B, IL1RL1, LY96, GCNT3, MMP10, MMP3, GADD45G and HSPA6 which were associated with immune response, metabolic processes, proteolysis, programmed cell death and unfolded protein response, and the down-regulation of TENM2, NEBL, KIFC1, CTDSP1, IGFBP5, LTBP1, NREP and MXD3 which were associated with cell adhesion, cytoskeletal organisation, phosphatase activity, signal transduction and transcription regulator activity. Of these 17 genes, 3 up- and 3 down-regulated genes were selected and validated, and the expression patterns determined from real-time PCR were consistent with the microarray results (Figure 1).

![Figure 1. Validation of mRNA expression of selected genes from microarray data by quantitative real time PCR.](image-url)
4. Discussion

Treatment of HeLa and CaSki cells with MS17 reveals an expression profile that contained common gene targets. This is interesting because although HeLa and CaSki are both infected with high risk subtypes that cause cervical cancer, both cell lines are derived from different sources such that CaSki is of squamous origin, while HeLa is an adenocarcinoma. Our results suggest that the 17 commonly regulated genes are important to specific biological functions and may be implicated in the anticancer activity of this curcumin analogue. Identification of common gene targets in cervical cancer cells despite being infected with different

Table 1

| GO term                        | Gene symbol | Genbank accession | Description                                      | Fold change (6 µM) | Fold change (9 µM) | P value |
|-------------------------------|-------------|-------------------|-------------------------------------------------|--------------------|--------------------|---------|
| Up-regulated                  |             |                   |                                                  |                    |                    |         |
| Chromatin organization        | NAP1L2      | NM_021963         | Nucleosome assembly protein 1-like 2            | 22.8               | 56.6               | 0.004   |
| Epidermis development         | SPPR2A      | NM_005988         | Small proline-rich protein 2A                  | 27.6               | 82.7               | 0.001   |
| Immune response               | *CCL26      | NM_006072         | Chemokine (C-C motif) ligand 26                | 60.7               | 115.2              | 0.002   |
|                              | *DEFB103B   | NM_018661         | Defensin, beta 103B                            | 35.4               | 78.4               | 0.001   |
|                              | *ILIR1      | NM_016232         | Interleukin 1 receptor-like 1                  | 27.2               | 74.9               | 0.001   |
|                              | *IL19       | NM_015364         | Lymphocyte antigen 96                          | 31.1               | 67.1               | 0.003   |
| Metabolic process             | REG3G       | NM_001008387      | Regenerating islet-derived 3 gamma             | 14.0               | 36.3               | 0.005   |
| Programmed cell death         | *GCTF3      | NM_004751         | Glucosaminyl (N-acetyl) transferase 3, mucin type | 40.0               | 92.6               | 0.001   |
|                              | AGMO        | NM_001004320      | Alkylglycerol monoxygenase                     | 18.5               | 55.8               | 0.006   |
| Protein ubiquitination        | *GADD45G    | NM_006705         | Growth arrest and DNA-damage-inducible, gamma  | 40.7               | 146.0              | 0.013   |
| Proteolysis                   | IL24        | NM_001185156      | Interleukin 24                                 | 25.5               | 56.1               | 0.014   |
|                              | *GCNT3      | NM_006705         | Glucosaminyl (N-acetyl) transferase 3, mucin type | 40.7               | 146.0              | 0.013   |
|                              | AGMO        | NM_001004320      | Alkylglycerol monoxygenase                     | 18.5               | 55.8               | 0.006   |
| Receptor activity             | PAQ9        | NM_198504         | Progestin and adipoQ receptor family member IX | 11.6               | 32.7               | 0.037   |
|                              | IL24        | NM_001185156      | Interleukin 24                                 | 25.5               | 56.1               | 0.014   |
|                              | NEBR3       | NM_001285486      | Neuralized E3 ubiquitin protein ligase 3       | 31.5               | 69.8               | 0.015   |
| Transcription regulator activity | MYCT1     | NM_025107         | Myc target 1                                   | 29.7               | 82.6               | 0.004   |
| Unfolded protein response      | *HSPA6      | NM_002155         | Heat shock 70kDa protein 6 (HSP70B')           | 247.7              | 702.6              | 0.003   |
| Cell adhesion                 | *TENM2      | NM_001122679      | Teneurin transmembrane protein 2               | -3.4               | -10.2              | 0.008   |
|                              | FOS         | NM_005252         | FBZ murine osteosarcoma viral oncogene homolog  | -8.2               | -7.1               | 0.010   |
|                              | *NEBL       | NM_006393         | Nebulette                                      | -5.9               | -6.2               | 0.013   |
|                              | MTUS2       | NM_00103602       | Microtubule associated tumor suppressor candidate 2 | -2.9               | -6.1               | 0.004   |
|                              | *KIFC1      | NM_002263         | Kinesin family member C1                       | -3.7               | -5.3               | 0.003   |
|                              | RDX         | NM_001260492      | Radixin                                        | -2.9               | -4.5               | 0.028   |
| Metabolic process             | LGSN        | NM_016571         | Lengsin, lens protein with glutamine synthetase domain | -6.6               | -8.6               | 0.042   |
|                              | CYP24AA1    | NM_000782         | Cytochrome P450, family 24, subfamily A         | -5.5               | -6.8               | 0.012   |
| Phosphatase activity          | *CTDSP1     | NM_02198          | CTD (carboxy-terminal domain, RNA polymerase II, polypeptide A) small phosphatase 1 | -3.3               | -6.9               | 0.048   |
|                              | PRKCB       | NM_002738         | Protein kinase C, beta                         | -9.8               | -16.6              | 0.001   |
|                              | PANBFRB     | NM_002609         | Platelet-derived growth factor receptor, beta | -7.2               | -14.4              | 0.003   |
|                              | PLKX3D      | NM_001005473      | Phosphatidylinositol-specific phospholipase C, X domain containing 3 | -5.5               | -14.2              | 0.042   |
|                              | *KCBP5      | NM_000599         | Insulin-like growth factor protein 5            | -6.1               | -8.5               | 0.005   |
|                              | LTB2P       | NM_000428         | Latent transforming growth factor beta binding protein 2 | -4.0               | -7.4               | 0.008   |
|                              | *NREP       | NM_001142483      | Neuronal regeneration related protein           | -4.6               | -6.2               | 0.008   |
|                              | RAB26       | NM_014353         | RAB26, member RAS oncogene family              | -2.8               | -5.5               | 0.013   |
|                              | *LTPB1      | NM_026943         | Latent transforming growth factor beta binding protein 1 | -4.4               | -5.2               | 0.036   |
| Transcription regulator activity | MAP2K6     | NM_002758         | Mitogen-activated protein kinase kinase 6       | -2.7               | -4.8               | 0.004   |
|                              | BARX1       | NM_012570         | BARX homeobox 1                                | -3.6               | -5.0               | 0.011   |
|                              | *MAD3       | NM_031300         | MAX dimerization protein 3                     | -2.8               | -4.7               | 0.002   |

Selected DEGs are listed according to biological function as proposed by DAVID Functional Annotation Tables. P value denotes the P corrected value for this gene list. *Indicates commonly regulated DEGs in treated HeLa and CaSki cell lines.
HPV subtypes may suggest that targeting these genes could have therapeutic implications.

The largest proportion of differentially up-regulated genes is associated with immune response. Many members in this cluster encode cytokines which are involved in immune system regulation and inflammation processes. Four highly up-regulated immune response-associated transcripts that were common to both cell lines included CCL26, followed by DEFB103B, IL1RL1 and LY96. CCL26 encodes dendritic-cell specific chemokines that attract naïve lymphocytes and neutrophils; DEFB103B codifies human β-defensin-3; IL1RL1 expresses the receptor for interleukin-1 and LY96 responds to toll-like receptor 4 on dendritic cells. They are

Table 2
Selected genes mutually induced and repressed in CaSki cells following 4 µM and 6 µM treatment of MS17 at 24 h.

| GO term                  | Gene symbol | Genbank accession | Description                        | Fold change (4 µM) | Fold change (6 µM) | P value |
|--------------------------|-------------|-------------------|------------------------------------|--------------------|--------------------|---------|
| Up-regulated             |             |                   |                                    |                    |                    |         |
| Cytoskeleton organization| *ARC*       | NM_015193         | Activity-regulated cytoskeleton-associated protein | 2.8                | 36.1               | 0.004 1 |
| ER calcium homeostasis   | *TMTC1*     | NM_175861         | Transmembrane and tetratricopeptide repeat containing 1 | 21.4               | 61.9               | 0.001 7 |
| Immune response          | *DEFB103B*  | NM_018661         | Defensin, beta 103B                 | 30.5               | 89.9               | 0.000 5 |
|                          | *CCL26*     | NM_006072         | Chemokine (C-C motif) ligand 26     | 6.5                | 33.4               | 0.001 4 |
|                          | *IL1RL1*    | NM_016232         | Interleukin 1 receptor-like 1       | 6.2                | 22.1               | 0.000 9 |
|                          | *LY96*      | NM_015364         | Lymphocyte antigen 96              | 5.0                | 14.8               | 0.003 5 |
| Metabolic process        | *GCTN3*     | NM_004751         | Glucosaminyl (N-acetyl) transferase 3, mucin type | 6.3                | 25.0               | 0.000 9 |
|                          | *CTDSP1*    | NM_008188         | Crystallin, mu                      | 5.4                | 18.9               | 0.000 6 |
|                          | *PNNIBP3*   | NM_00151709       | Pancreatic lipase-related protein 3  | 7.2                | 18.0               | 0.000 8 |
|                          | *HKG1*      | NM_025130         | Hexokinase domain containing 1     | 3.8                | 7.6                | 0.002 2 |
| Programmed cell death    | *GADD45G*   | NM_006705         | Growth arrest and DNA-damage-inducible, gamma | 2.8                | 18.5               | 0.002 7 |
| Proteolysis              | *MMP10*     | NM_002425         | Matrix metalloproteinase 10 (stromelysin 2) | 46.6               | 347.9              | 0.001 4 |
|                          | *MMP3*      | NM_002422         | Matrix metalloproteinase 3 (stromelysin 1, progelatinase) | 7.6                | 26.3               | 0.002 2 |
| Signal transduction      | *F2RL2*     | NM_004101         | Coagulation factor II (thrombin) receptor-like 2 | 17.4               | 52.4               | 0.000 9 |
|                          | *NGNT2*     | NM_031498         | Guanine nucleotide binding protein (G protein), gamma transducing activity polypeptide 2 | 14.5               | 41.3               | 0.004 9 |
| Transcription regulator activity | *MAFB* | NM_005461         | V-maf avian musculoaponeurotic fibrosarcoma oncogene homolog B | 2.0                | 18.1               | 0.001 2 |
|                          | *ZFAND2A*   | NM_182491         | Zinc finger, AN1-type domain 2A     | 2.5                | 12.6               | 0.001 7 |
|                          | *E103*      | NM_001008394      | EP300 interacting inhibitor of differentiation 3 | 3.2                | 10.9               | 0.004 6 |
| Unfolded protein response| *HSPA6*     | NM_002155         | Heat shock 70kDa protein 6 (HSP70B') | 22.6               | 309.1              | 0.001 1 |
| Down-regulated           |             |                   |                                    |                    |                    |         |
| Cell adhesion            | *WISP2*     | NM_003881         | WNT1 inducible signaling pathway protein 2 | -3.8               | -9.7               | 0.003 8 |
|                          | *TENM2*     | NM_001122679      | Teneurin transmembrane protein 2    | -2.4               | -5.2               | 0.013 5 |
|                          | *FAT2*      | NM_001447         | FAT atypical cadherin 2             | -2.5               | -5.1               | 0.022 4 |
| Cell cycle               | *AURKB*     | NM_004217         | Aurora kinase B                    | -2.3               | -5.9               | 0.001 4 |
|                          | *PLK1*      | NM_005030         | Polo-like kinase 1                 | -2.4               | -4.7               | 0.010 3 |
| Cell proliferation       | *MKI67*     | NM_002417         | Marker of proliferation Ki-67       | -2.7               | -6.1               | 0.005 5 |
| Chromosome segregation   | *CENPF*     | NM_016343         | Centromere protein F, 350/400kDa    | -2.6               | -4.7               | 0.004 4 |
|                          | *NEK2*      | NM_002497         | NIMA-related kinase 2              | -2.3               | -4.5               | 0.004 4 |
| Cytoskeleton organization| *KIF20A*    | NM_005733         | Kinesin family member 20A          | -2.8               | -7.4               | 0.003 2 |
|                          | *KIFC1*     | NM_002263         | Kinesin family member C1           | -2.0               | -4.8               | 0.000 8 |
|                          | *KIF4A*     | NM_012310         | Kinesin family member 4A           | -2.7               | -4.6               | 0.007 2 |
| DNA replication          | *T0PA*      | NM_001067         | Topoisomerase (DNA) II alpha 170kDa | -2.0               | -5.8               | 0.001 4 |
| Phosphatase activity     | *CDTDP1*    | NM_021198         | CTD (carboxy-terminal domain, RNA polymerase) II, polypeptide A small phosphatase 1 | -2.2               | -5.9               | 0.016 9 |
| Signal transduction      | *WNT4*      | NM_030761         | Wntless-type MMTV integration site family, member 4 | -3.9               | -7.7               | 0.004 1 |
|                          | *IGFBP5*    | NM_000599         | Insulin-like growth factor protein 5 | -3.2               | -7.5               | 0.000 8 |
|                          | *ARHGEF39*  | NM_032818         | Rho guanine nucleotide exchange factor (GEF) 39 | -3.3               | -6.7               | 0.005 2 |
|                          | *LTBP1*     | NM_206943         | Latent transforming growth factor beta binding protein 1 | -4.6               | -5.1               | 0.001 7 |
| Transcription regulator activity | *NRN* | NM_001142483      | Neuronal regeneration related protein | -2.6               | -4.0               | 0.002 5 |
|                          | *MAX3*      | NM_031300         | MAX dimerization protein 3          | -2.7               | -8.3               | 0.002 8 |

Selected DEGs are listed according to biological function as proposed by DAVID Functional Annotation Tables. P value denotes the P -corrected value for this gene list. *Indicates commonly regulated DEGs in treated HeLa and CaSki cell lines.
respectively involved in the repression of cancer cell migration[20], growth[21,22] and the mediation of anticancer immunity[23]. The findings suggest that induction of an immune response, inhibition of cell migration and growth could be potential mechanisms by which MS17 exhibits anticancer activity on HeLa and CaSki cells.

The metabolism-associated GCNT3 encodes a beta-6-N-acetylglucosamine-transferase which catalyses O-glycan branching on mucin-type glycoproteins. Alterations in the O-glycosylation of mucins often accompany cancer development and the overexpression of GCNT3 reportedly suppresses cell adhesion, motility and invasion of colorectal cancer cells[24] and may contribute towards anti-tumorigenic activity in treated HeLa and CaSki cells. MS17 treatment positively modulated the increased expression of proteolytic matrix metalloproteinases, specifically of MMP10 and MMP3 which degrade the extracellular matrix[25]. MMP10 is commonly implicated in inflammatory diseases and may be secreted by T-lymphocytes to assist in extracellular matrix degradation[26] during inflammation or an immune response. Cross-talk between matrix metalloproteinases suggests that they may possess profound anti-tumorigenic effects. Squamous cell carcinoma tumours in MMP3-null mice exhibited enhanced tumour progression and were inversely correlated with leukocyte infiltration[27]. Therefore the up-regulation of matrix metalloproteinases by MS17 indicates the potential modulation over the proteolytic extracellular matrix degradation of cervical cancer cells to exert its anti-tumorigenic effects. The exact mechanism by which this occurs however needs to be investigated further.

The up-regulation of programmed cell death associated gene GADD45G demonstrated that increasing the treatment dose by 1.5-fold showed almost 3.6-fold up-regulation in MS17 treated HeLa cells and 6.6-fold up-regulation in CaSki cells. GADD45G codifies the expression of DNA damage inducible proteins which is activated by heat shock or UV irradiation stimuli, a response which is abolished in approximately 50% of cervical cancer tumours[28,29]. Notably, its expression is up-regulated following exposure to curcumin treatment, DNA damage and genotoxic stress and induces cell cycle arrest, apoptosis and inhibits cell growth[30,31] and its induction could contribute to the apoptotic cell death mechanism of MS17 in treated HeLa and CaSki cells.

The heat shock gene HSPA6 which encodes the stress-inducible Hsp70 protein, is the topmost mutually up-regulated transcript in HeLa cells and demonstrates 13.7-fold up-regulation in response to increasing treatment dose in CaSki cells. Heat shock proteins act as protein chaperones to prevent protein misfolding and Hsp70 expression is commonly up-regulated during cellular oxidative stress which promotes tumour cell growth and contributes to genomic instability and DNA damage in cancer cells. However, the overexpression of oxidative stress also induces cancer cell death[32] and the induction of heat shock protein expression in response to anticaner compounds is not uncommon. Treatment with elescomol triggered apoptosis in melanoma cancer cells by inducing a transcriptional gene profile characteristic of an oxidative stress response, which also included HSPA6 as its top most up-regulated transcript[32]. Notably treatment of HeLa and leukaemia cells with curcumin and exposure of melanoma cells with curcumin analogue D6 induced the up-regulation of HSPA6, correlating strongly with cellular toxicity and was suggested to cause extreme endoplasmic reticulum stress resulting in apoptotic cell death[33-35]. This may thus reflect a similar mechanism by which MS17 up-regulates HSPA6 expression to modulate oxidative stress responses and trigger apoptosis induction in treated cells thus contributing to anti-tumorigenesis.

The expression of cell adhesion-associated TENM2 is down-regulated in both cell lines following MS17 treatment. TENM2 encodes a transmembrane protein that enhances proliferation, promotes cell adhesion, facilitates microtubule organization[36] and is up-regulated by more than 250-fold in vincristine-resistant ovarian cancer cells[37]. The suppression of TENM2 by MS17 could disrupt adhesive contact between cells and mediate anti-proliferative activity in treated HeLa and CaSki cells.

Cytoskeleton organizing genes NEBL and KIFC1 are also down-regulated by MS17 treatment in both cell lines. NEBL codifies nebullete, an actin protein involved in cytoskeletal organization. The up-regulation of NEBL stimulates cell migration[38] while silencing of a related family member, Lasp1, in cell lines abrogates metastasis[39]. KIFC1 encodes microtubule motor proteins that function during spindle formation. The down-regulation of KIFC1 may destabilize spindle assembly, trigger cell cycle arrest and reduce cell viability[40]. Thus the repression of cytoskeletal organisation genes indicates the role of MS17 in modulating an anchorage network that is important for chromosome stability in mitosis.

The nuclear phosphatase expressed by CTDSP1 regulates gene expression by selective dephosphorylation of phosphoserine 5 within RNA polymerase II and is commonly associated with the silencing of neuronal genes[41]. Its down-regulation by MS17 in cervical cancer cells suggests the potential modulation of transcriptional regulation to inhibit cell survival. IGFBP5, LTBP1 and NREP are grouped under signal transduction ontologies. IGFBP5 encodes IGF-binding proteins which are highly expressed in CIN tissues[42] and regulates the survival of cervical cancer cells by conferring it with anti-apoptotic properties[43]. The down-regulation of IGFBP5 expression by MS17 suggests the reactivation of apoptosis in HeLa and CaSki cells which potentially contributes to cell death. LTBP1 encodes a latent TGFβ binding protein which contributes towards glioma cell malignancy while silencing is shown to reduce TGFβ activity[44] suggesting an important modulatory effect of LTBP1 over malignant tumour phenotypes. On the other hand, NREP encodes a neural regeneration protein but demonstrates RAC1-mediated involvement in glioma cell motility[45]. Hence the suppression of NREP by MS17 targets the disruption of actin cytoskeletal organization of HeLa and CaSki cells and impairs malignant cell proliferation and motility. Furthermore, MXD3 encodes a MAD family transcription
factor which contributes to cell proliferation upon up-regulation but demonstrates anti-proliferative activity following MDX3-specific silencing[46] which may result in the suppression of cervical cancer proliferation following MS17 treatment.

In conclusion, the dose-dependent modulation of high ranking genes demonstrates the notable regulation of 17 genes that are common to both cell lines, suggesting the possibility that MS17 exerts antitumor effects on pathways linked to immune response, metabolism, proteolysis, apoptosis, unfolded protein response, cell adhesion, cytoskeletal organization, phosphatase activity, signal transduction and transcription regulator activity. Despite the differing biological properties of HPV-18 infected HeLa and HPV-16 infected CaSki cells, the common regulation of these genes indicates shared therapeutic targets and mechanism of action by MS17 in cervical cancer cells. Thus the findings of this study present an insight into the potential antitumor activity of MS17 in cervical cancer and identify key biological targets that serve as a basis for future investigation.

Conflict of interest statement
The authors declare no conflict of interest.

Acknowledgments
The authors are grateful to the Jeffrey Cheah School of Medicine and Health Sciences, Monash University Malaysia for providing the research facilities and support.

References

[1] Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. Globocan 2012 v1.0, Cancer incidence and mortality worldwide: IARC cancerbase No. 11. Lyon, France: International Agency for Research on Cancer. [Online] Available from: http://globocan.iarc.fr. [Accessed on: September 1, 2016].

[2] Maher DM, Bell MC, O’Donnell EA, Kohaar I, Hedau S, Bharti AC, et al. Curcumin suppresses human papillomavirus oncoproteins, restores p53, Rb, and PTPN13 proteins and inhibits benzo[a]pyrene-induced upregulation of HPV E7. Mol Carcinog 2011; 50: 47-57.

[3] Mishra A, Kumar R, Tyagi A, Kohaar I, Hedau S, Bharti AC, et al. Curcumin modulates cellular AP-1, NF-xB, and HPV16 E6 proteins in oral cancer. Eancermedicalscience 2015; 9: 525.

[4] Goodwin EC, DiMaio D. Repression of human papillomavirus oncopgenes in HeLa cervical carcinoma cells causes the orderly reactivation of dormant tumor suppressor pathways. Proc Natl Acad Sci U S A 2000; 97: 12513-12518.

[5] Dang YP, Yuan XY, Tian R, Li DG, Liu W, et al. Curcumin improves the paclitaxel-induced apoptosis of HPV-positive human cervical cancer cells via the NF-κappaB-p53-caspase-3 pathway. Exp Ther Med 2015; 9: 1470-1476.

[6] Singh M, Singh N. Molecular mechanism of curcumin induced cytotoxicity in human cervical carcinoma cells. Mol Cell Biochem 2009; 325: 107-119.

[7] Divya CS, Pillai MR. Antitumor action of curcumin in human papillomavirus associated cells involves downregulation of viral oncogenes, prevention of NFκB and AP-1 translocation, and modulation of apoptosis. Mol Carcinog 2006; 45: 320-332.

[8] Ohori H, Yamakoshi H, Tomizawa M, Shibuya M, Kakudo Y, Takahashi A, et al. Synthesis and biological analysis of new curcumin analogues bearing an enhanced potential for the medicinal treatment of cancer. Mol Cancer Ther 2006; 5: 2563-2571.

[9] Sato A, Kudo C, Yamakoshi H, Uehara Y, Ohori H, Ishioka C, et al. Curcumin analog GO-Y030 is a novel inhibitor of IKKbeta that suppresses NF-κappaB signaling and induces apoptosis. Cancer Sci 2011; 102: 1045-1051.

[10] Kudo C, Yamakoshi H, Sato H, Nanjo H, Ohori H, Ishioka C, et al. Synthesis of 86 species of 1,5-diaryl-3-oxo-1,4-pentadienones analogs of curcumin can yield a good lead in vitro. BMC Pharmacol 2011; 11: 4.

[11] Selvendiran K, Kuppusamy ML, Bratasz A, Tong L, Rivera BK, Rink C, et al. Inhibition of vascular smooth-muscle cell proliferation and arterial restenosis by HO-3867, a novel synthetic curcuminoid, through up-regulation of PTEN expression. J Pharmocol Exp Ther 2009; 329: 959-966.

[12] Selvendiran K, Tong L, Vishwanath S, Bratasz A, Trigg NJ, Kutala VK, et al. EF24 induces G2/M arrest and apoptosis in cisplatin-resistant human ovarian cancer cells by increasing PTEN expression. J Biol Chem 2007; 282: 28609-28618.

[13] Tan X, Sidell N, Mancini A, Huang RP, Wang S, Horowitz IR, et al. Multiple anticancer activities of EF24, a novel curcumin analog, on human ovarian carcinoma cells. Reprod Sci 2010; 17: 931-940.

[14] Kasinski AL, Du Y, Thomas SL, Zhao J, Sun SY, Khuri FR, et al. Inhibition of IκB kinase-nuclear factor-xB signaling pathway by 3,5-bis(2-flurobenzylidene)piperidin-4-one (EF24), a novel monoketone analog of curcumin. Mol Pharmacol 2008; 74: 654-661.

[15] Zhang X, Wang R, Chen G, Dejean L, Chen QH. The effects of curcumin-based compounds on proliferation and cell death in cervical cancer cells. Anticancer Res 2015; 35: 5293-5298.

[16] Wang R, Chen C, Zhang X, Chen G, Sarabia C, Zhang Q, et al. Structure-activity relationship and pharmacokinetic studies of 1,5-diheteroarylpenta-1,4-dien-3-one (EF24), a novel monoketone analog of curcumin. Mol Pharmacol 2007; 282: 28609-28618.

[17] Zaman MS, Chauhan N, Vallapu MM, Gara RK, Maher DM, Kumari S, et al. Curcumin nanoformulation for cervical cancer treatment. Sci Rep 2016; 6: 20051.

[18] Paulraj F, Abas F, Lajis NH, Othman I, Hassan SS, Naidu R. The curcumin analogue 1,5-bis(2-hydroxyphenyl)-1,4-pentadiene-3-one induces apoptosis and downregulates E6 and E7 oncogene expression in HPV16 and HPV18-infected cervical cancer cells. Molecules 2015; 20(7): 11830-11860.
[19] Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009; 4: 44-57.

[20] Uraki S, Sugimoto K, Shiraki K, Tameda M, Inagaki Y, Ogura S, et al. Human beta-defensin-3 inhibits migration of colon cancer cells via downregulation of metastasis-associated 1 family, member 2 expression. Int J Oncol 2014; 45: 1059-1064.

[21] Haga Y, Yanagisawa K, Ohno-Ozaki H, Tominaga S, Masuzawa T, Iwahana H. The effect of ST2 gene product on anchorage-independent growth of a glioblastoma cell line, T98G. Eur J Biochem 2003; 270: 163-170.

[22] O'Donnell C, Mahmoud A, Keane J, Murphy C, White D, Carey S, et al. Lymphocytes express a member of the Matrix Metalloproteinase gene family. Br J Cancer 2016; 114: 37-43.

[23] Nakamura H, Fujii Y, Ohuchi E, Yamamoto E, Okada Y. Activation of the antitumorigenic role for the IL-33 receptor, ST2L, in colon cancer. Mol Cancer Ther 2008; 7: 4190-4196.

[24] Dunsmore KE, Chen PG, Wong HR. Curcumin, a medicinal herbal compound capable of inducing the heat shock response. Crit Care Med 2001; 29: 2199-2204.

[25] Debackman J, Schubert R, Chiquet-Ehrismann R, Miller DJ. Deciphering teneurin domains that facilitate cellular recognition, cell-cell adhesion, and neurite outgrowth using atomic force microscopy-based single-cell force spectroscopy. Nano Lett 2013; 13: 2937-2946.

[26] Buys TP, Chari R, Lee EH, Zhang M, MacAulay C, Lam S, et al. Genetic changes in the evolution of multidrug resistance for cultured human ovarian cancer cells. Genes Chromosome Cancer 2007; 46: 1069-1079.

[27] Emerenciano M, Kowarz E, Karl K, de Almeida Lopes B, Scholz B, Bracharz S, et al. Functional analysis of the two reciprocal fusion genes MLL-NEBL and NEBL-MLL reveal their oncogenic potential. Cancer Lett 2013; 332: 30-34.

[28] Zhang H, Chen X, Bollag WB, Bollag RJ, Sheehan DJ, Chew CS, et al. Lasp1 gene disruption is linked to enhanced cell migration and tumor formation. Physiol Genomics 2009; 38: 372-385.

[29] Panu V, Rida PC, Ogden A, Turaga RC, Donthamsetty S, Bowen NJ, et al. HSET overexpression fuels tumor progression via centrosome clustering-independent mechanisms in breast cancer patients. Oncotarget 2015; 6: 6076-6091.

[30] Yeo M, Lee SK, Lee B, Ruiz EC, Pfaff SL, Gill GN. Small CTD phosphatases function in silencing neuronal gene expression. Science 2005; 307: 596-600.

[31] Hou XJ, Zhang YZ, Liu X, Meng LH, Qiao YB. Expressions of IGFBP-5, cFLIP in cervical intraepithelial neoplasia, cervical carcinoma and their clinical significances: a molecular pathology. J Exp Clin Cancer Res 2009; 28: 70.

[32] Perks CM, McCaig C, Holly JM. Differential insulin-like growth factor (IGF)-independent interactions of IGF binding protein-3 and IGF binding protein-5 on apoptosis in human breast cancer cells. Involvement of the mitochondria. J Cell Biochem 2000; 80: 248-258.

[33] Trittischler I, Gramatziki D, Capper D, Mittelbronn M, Meyermann R, Saharinen J, et al. Modulation of TGF-beta activity by latent TGF-beta-mitochondria. J Cell Physiol 2000; 183: 530-540.

[34] Mariani L, McDonough WS, Hoelzinger DB, Beaudry C, Kaczmarek E, Coons SW, et al. Identification and validation of P311 as a glioblastoma invasion gene using laser capture microdissection. Cancer Res 2001; 61: 4190-4196.

[35] Barisone GA, Ngo T, Tran M, Cortes D, Shahi MH, Nguyen TV, et al. Role of MXD3 in proliferation of DAOY human medulloblastoma cells. PLoS One 2012; 7: e38508.